Literature DB >> 15775996

Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.

Jennifer A Wargo1, Lana Y Schumacher, Begonya Comin-Anduix, Vivian B Dissette, John A Glaspy, William H McBride, Lisa H Butterfield, James S Economou, Antoni Ribas.   

Abstract

Tumor antigen gene-modified dendritic cells (DC) generates robust antigen-specific protective antitumor responses. Though the role of CD4 positive and CD8 positive cells in the immunological response to gene-modified DC has been well-characterized, the role of NK cells in this response has been somewhat less clear. Owing to the significant contribution of innate immunity in other model systems, we postulated that NK cells would hold a critical position in the generation of an immune response following immunization with tumor antigen-engineered DC. Immunization with MART-1 melanoma antigen-engineered DC in C57BL/6 mice resulted in the generation of antigen-specific cytotoxic T lymphocytes and in vivo protective responses to the murine B16 melanoma. These responses were dependent on the presence of functional NK cells, although NK cells alone were not sufficient in generating protective responses. Adoptive transfer of NK cells into an NK-deficient but T-cell-competent environment restored the protective response to gene-modified DC immunization. In conclusion, protective immunity after tumor antigen gene-modified DC immunization requires collaboration between CD4+ and CD8+ T cells and NK cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15775996     DOI: 10.1038/sj.cgt.7700818

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  11 in total

Review 1.  NK cells: key to success of DC-based cancer vaccines?

Authors:  Eva Lion; Evelien L J M Smits; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-08-20

2.  Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15.

Authors:  Lazar Vujanovic; David E Szymkowski; Sean Alber; Simon C Watkins; Nikola L Vujanovic; Lisa H Butterfield
Journal:  Blood       Date:  2010-04-29       Impact factor: 22.113

Review 3.  New approaches to the development of adenoviral dendritic cell vaccines in melanoma.

Authors:  Lisa H Butterfield; Lazar Vujanovic
Journal:  Curr Opin Investig Drugs       Date:  2010-12

Review 4.  Engineering dendritic cells to enhance cancer immunotherapy.

Authors:  Jeanette E Boudreau; Aude Bonehill; Kris Thielemans; Yonghong Wan
Journal:  Mol Ther       Date:  2011-04-05       Impact factor: 11.454

5.  Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.

Authors:  Lisa H Butterfield; Begonya Comin-Anduix; Lazar Vujanovic; Yohan Lee; Vivian B Dissette; Jin-Quan Yang; Hong T Vu; Elizabeth Seja; Denise K Oseguera; Douglas M Potter; John A Glaspy; James S Economou; Antoni Ribas
Journal:  J Immunother       Date:  2008-04       Impact factor: 4.456

6.  Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10.

Authors:  Lazar Vujanovic; Wenners Ballard; Stephen H Thorne; Nikola L Vujanovic; Lisa H Butterfield
Journal:  Oncoimmunology       Date:  2012-07-01       Impact factor: 8.110

7.  Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.

Authors:  Leeann T Blalock; Jennifer Landsberg; Michelle Messmer; Jian Shi; Angela D Pardee; Ronald Haskell; Lazar Vujanovic; John M Kirkwood; Lisa H Butterfield
Journal:  Oncoimmunology       Date:  2012-05-01       Impact factor: 8.110

8.  A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination.

Authors:  Aurélie Collignon; Adriana Teodora Perles-Barbacaru; Stéphane Robert; Françoise Silvy; Emmanuelle Martinez; Isabelle Crenon; Sébastien Germain; Stéphane Garcia; Angèle Viola; Dominique Lombardo; Eric Mas; Evelyne Béraud
Journal:  Oncotarget       Date:  2015-09-15

Review 9.  Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme.

Authors:  Liu Yang; Geng Guo; Xiao-yuan Niu; Jing Liu
Journal:  Biomed Res Int       Date:  2015-06-17       Impact factor: 3.411

10.  GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.

Authors:  Okjae Lim; Yuna Lee; Hyejin Chung; Jung Hyun Her; Sang Mi Kang; Mi-young Jung; Bokyung Min; Hyejin Shin; Tae Min Kim; Dae Seog Heo; Yu Kyeong Hwang; Eui-Cheol Shin
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.